Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
DE000A0B65S3
Mon, 03.04.2023
PAION AG
PAION receives European Commission approval of remimazolam for the Induction and maintenance of general anesthesia in adults
Aachen (Germany), 03 April 2023 – The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) announces that today the European Commission (EC) has approved remimazolam f [ … ]
Mon, 03.04.2023
PAION AG
PAION receives European Commission approval of remimazolam for the Induction and maintenance of general anesthesia in adults
Aachen (Germany), 03 April 2023 – The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) announces that today the European Commission (EC) has approved remimazolam f [ … ]
Fri, 27.01.2023
PAION AG
PAION receives positive CHMP opinion recommending approval of remimazolam for the induction and maintenance of general anesthesia in adults
Aachen (Germany), 27 January 2023 – The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) announces that today the European Medicines Agency’s Committ [ … ]
Wed, 14.12.2022
PAION AG
Public disclosure of inside information pursuant to Article 17 of the Regulation (EU) No 596/2014 (Market Abuse Regulation)
PAION AG convenes extraordinary general meeting for capital reductions by redemption and consolidation of sharesAachen, December 14, 2022 – The Management Board of specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; [ … ]
Wed, 14.12.2022
PAION AG
Public disclosure of inside information pursuant to Article 17 of the Regulation (EU) No 596/2014 (Market Abuse Regulation)
PAION AG convenes extraordinary general meeting for capital reductions by redemption and consolidation of sharesAachen, December 14, 2022 – The Management Board of specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; [ … ]
Wed, 30.11.2022
PAION AG
Ad-hoc announcement pursuant to Art. 17 of the EU Market Abuse Regulation (MAR)
PAION AG: CEO Dr. James Phillips leaves the Company as of 30 November 2022, appointment of Supervisory Board member Gregor Siebert as member and new CEO until 30 November 2023
Aachen (Germany), 30 November 2022 – PAION AG (ISIN: DE000A0B65S3 / WKN A0B65S) announces [ … ]
Wed, 30.11.2022
PAION AG
Ad-hoc announcement pursuant to Art. 17 of the EU Market Abuse Regulation (MAR)
PAION AG: CEO Dr. James Phillips leaves the Company as of 30 November 2022, appointment of Supervisory Board member Gregor Siebert as member and new CEO until 30 November 2023
Aachen (Germany), 30 November 2022 – PAION AG (ISIN: DE000A0B65S3 / WKN A0B65S) announces [ … ]
Tue, 15.11.2022
PAION AG
Ad-hoc announcement pursuant to Art. 17 of the EU Market Abuse Regulation (MAR)PAION AG raises EBITDA forecast for fiscal year 2022
Aachen (Germany), 15 November 2022 – PAION AG (ISIN: DE000A0B65S3 / WKN A0B65S) announces that, based on the results for the first nine months of 2022, it is raising the outlook for the full year 2022 published with t [ … ]
Tue, 15.11.2022
PAION AG
Ad-hoc announcement pursuant to Art. 17 of the EU Market Abuse Regulation (MAR)PAION AG raises EBITDA forecast for fiscal year 2022
Aachen (Germany), 15 November 2022 – PAION AG (ISIN: DE000A0B65S3 / WKN A0B65S) announces that, based on the results for the first nine months of 2022, it is raising the outlook for the full year 2022 published with t [ … ]
Wed, 27.04.2022
PAION AG
PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA
- EUR 3.5 million upfront payment to PAION
- 20% royalties on net sales
Aachen (Germany), 27 April 2022 - PAION AG, a specialty pharma company (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8), and Cristália Produtos [ … ]